Clinical Pharmacology Characterization of the First‐In‐Class Oncolytic Viral Therapy T‐VEC in Adults and Pediatric Subjects.
Oncolytic viruses are an emerging class of immunotherapies for cancer treatment. Talimogene laherparepvec (T‐VEC) is a first‐in‐class oncolytic virus approved globally for advanced melanoma. Herein, we describe the quantitative clinical pharmacology aspects of T‐VEC that supported the development of...
| Publicado en: | Journal of Clinical Pharmacology Vol. 66; no. 1; pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jan2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |